Undervalued with collaboration news to come17 Sep 2025 10:52
“albeit the board believes the shares remain undervalued. The Company reconfirms its trading and operation position set out in the trading update of 26 August 2025 with FDA De Novo discussions continuing to progress and work ongoing to close out the remaining deficiencies. Collaboration discussions on potential US and EU test distribution are progressing with a major distributer. The Company looks forward to updating the market at its interim results on Tuesday, 30 September 2025”.